Eupatolide inhibits the TGF‑β1‑induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5 Corrigendum in /10.3892/ol.2018.8427

Boldbaatar,Ariundavaa; Lee,Sunyi; Han,Sora; Jeong,Ae Lee; Ka,Hye In; Buyanravjikh,Sumiyasuren; Lee,Jeong Hyung; Lim,Jong‑Seok; Lee,Myung Sok; Yang,Young

doi:10.3892/ol.2017.6957

Eupatolide inhibits the TGF‑β1‑induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5

Corrigendum in: /10.3892/ol.2018.8427

Authors:
- Ariundavaa Boldbaatar
- Sunyi Lee
- Sora Han
- Ae Lee Jeong
- Hye In Ka
- Sumiyasuren Buyanravjikh
- Jeong Hyung Lee
- Jong‑Seok Lim
- Myung Sok Lee
- Young Yang
View Affiliations

Affiliations: Graduate School of Biological Science, Sookmyung Women's University, Seoul 04310, Republic of Korea, Research Center for Women's Disease, Department of Biological Science, Sookmyung Women's University, Seoul 04310, Republic of Korea, Department of Biochemistry, Kangwon National University, Chuncheon 24341, Republic of Korea, Department of Biological Science, Sookmyung Women's University, Seoul 04310, Republic of Korea
Published online on: September 15, 2017 https://doi.org/10.3892/ol.2017.6957
Pages: 6031-6039
Copyright: © Boldbaatar et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epithelial‑mesenchymal transition (EMT) is a hallmark of cancer metastasis, and the associated molecular signaling pathways are regarded as therapeutic targets for cancer treatment. Thus, suppressing EMT with a natural chemical compound may be of therapeutic benefit. Eupatolide is a natural chemical compound extracted from the medicinal plant Inula britannica, which is used in Eastern Asia to treat bronchitis, disorders of the digestive system and inflammation. Besides the anti‑inflammatory function of eupatolide, the present study found that eupatolide suppressed the migration and invasion of breast cancer cells, which was associated with the downregulation of vimentin in MDA‑MB‑231 cells and the upregulation of E‑cadherin in MCF‑7 cells. Treatment with eupatolide also significantly inhibited the migration and invasion of breast cancer cells that had been stimulated with transforming growth factor‑β1 (TGF‑β1). Eupatolide also suppressed TGF‑β1‑induced EMT via downregulation of mothers against decapentaplegic homolog 3 (SMAD3) phosphorylation and transcriptional repression of TGF‑β receptor 1 (ALK5). In addition to this canonical pathway, the non‑canonical protein kinase B (AKT) and extracellular signal‑regulated kinase (ERK) pathways were also inhibited by eupatolide treatment. In summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5‑SMAD3 signaling pathway and the non‑canonical ERK and AKT signaling pathways.

View Figures

View References

1	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kalluri R and Weinberg RA: The basics of epithelial-mesenchytnal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
4	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tam WL and Weinberg RA: The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lin YC, Lee YC, Li LH, Cheng CJ and Yang RB: Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 127:85–100. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wu Y and Zhou BP: Snail: More than EMT. Cell Adh Migr. 4:199–203. 2010. View Article : Google Scholar : PubMed/NCBI
8	Marcucci F, Stassi G and De Maria R: Epithelial-mesenchymal transition: A new target in anticancer drug discovery. Nat Rev Drug Discov. 15:311–325. 2016. View Article : Google Scholar : PubMed/NCBI
9	Heldin CH, Vanlandewijck M and Moustakas A: Regulation of EMT by TGFβ in cancer. FEBS Lett. 586:1959–1970. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wakefield LM and Roberts AB: TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kubiczkova L, Sedlarikova L, Hajek R and Sevcikova S: TGF-β - an excellent servant but a bad master. J Transl Med. 10:1832012. View Article : Google Scholar : PubMed/NCBI
12	Cunha SI and Pietras K: ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 117:6999–7006. 2011. View Article : Google Scholar : PubMed/NCBI
13	Whitman M and Raftery L: TGFbeta signaling at the summit. Development. 132:4205–4210. 2005. View Article : Google Scholar : PubMed/NCBI
14	Curado F, Spuul P, Egaña I, Rottiers P, Daubon T, Veillat V, Duhamel P, Leclercq A, Gontier E and Génot E: ALK5 and ALK1 play antagonistic roles in transforming growth factor β-induced podosome formation in aortic endothelial cells. Mol Cell Biol. 34:4389–4403. 2014. View Article : Google Scholar : PubMed/NCBI
15	Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schniewind B, Groth S, Müerköster S Sebens, Sipos B, Schäfer H, Kalthoff H, Fändrich F and Ungefroren H: Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene. 26:4850–4862. 2007. View Article : Google Scholar : PubMed/NCBI
17	Khan AL, Hussain J, Hamayun M, Gilani SA, Ahmad S, Rehman G, Kim YH, Kang SM and Lee IJ: Secondary metabolites from Inula britannica L. and their biological activities. Molecules. 15:1562–1577. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lee YH, Lee NK and Paik HD: Antimicrobial characterization of inula britannica against helicobacter pylori on gastric condition. J Microbiol Biotechnol. 26:1011–1017. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lee J, Hwangbo C, Lee JJ, Seo J and Lee JH: The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol Rep. 23:229–237. 2010.PubMed/NCBI
20	Kim N, Hwangbo C, Lee S and Lee JH: Eupatolide inhibits PDGF-induced proliferation and migration of aortic smooth muscle cells through ROS-dependent heme oxygenase-1 induction. Phytother Res. 27:1700–1707. 2013. View Article : Google Scholar : PubMed/NCBI
21	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lee S, Jeong AL, Park JS, Han S, Jang CY, Kim KI, Kim Y, Park JH, Lim JS, Lee MS and Yang Y: IK-guided PP2A suppresses Aurora B activity in the interphase of tumor cells. Cell Mol Life Sci. 73:3375–3386. 2016. View Article : Google Scholar : PubMed/NCBI
23	Jin HZ, Lee D, Lee JH, Lee K, Hong YS, Choung DH, Kim YH and Lee JJ: New sesquiterpene dimers from Inula britannica inhibit NF-kappaB activation and NO and TNF-alpha production in LPS-stimulated RAW264.7 cells. Planta Med. 72:40–45. 2006. View Article : Google Scholar : PubMed/NCBI
24	Lee S, Han S, Jeong AL, Park JS and Yang Y: Depletion of IK causes mitotic arrest through aberrant regulation of mitotic kinases and phosphatases. FEBS Lett. 588:2844–2850. 2014. View Article : Google Scholar : PubMed/NCBI
25	Sinha C, Ren A, Arora K, Moon CS, Yarlagadda S, Zhang W, Cheepala SB, Schuetz JD and Naren AP: Multi-drug resistance protein 4 (MRP4)-mediated regulation of fibroblast cell migration reflects a dichotomous role of intracellular cyclic nucleotides. J Biol Chem. 288:3786–3794. 2013. View Article : Google Scholar : PubMed/NCBI
26	Li L, Qi L, Liang Z, Song W, Liu Y, Wang Y, Sun B, Zhang B and Cao W: Transforming growth factor-β1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells. Int J Mol Med. 36:113–122. 2015. View Article : Google Scholar : PubMed/NCBI
27	Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat. 132:75–85. 2012. View Article : Google Scholar : PubMed/NCBI
28	Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, Giovinazzo G, Santino A, Storelli C and Maffia M: Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 310:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
29	van Roy F and Berx G: The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756–3788. 2008. View Article : Google Scholar : PubMed/NCBI
30	Chao YL, Shepard CR and Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 9:1792010. View Article : Google Scholar : PubMed/NCBI
31	Kocic J, Bugarski D and Santibanez JF: SMAD3 is essential for transforming growth factor-β1-induced urokinase type plasminogen activator expression and migration in transformed keratinocytes. Eur J Cancer. 48:1550–1557. 2012. View Article : Google Scholar : PubMed/NCBI
32	Pannu J, Nakerakanti S, Smith E, ten Dijke P and Trojanowska M: Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem. 282:10405–10413. 2007. View Article : Google Scholar : PubMed/NCBI
33	Wrighton KH, Lin X and Feng XH: Phospho-control of TGF-beta superfamily signaling. Cell Res. 19:8–20. 2009. View Article : Google Scholar : PubMed/NCBI
34	Cantelli G, Crosas-Molist E, Georgouli M and Sanz-Moreno V: TGFBeta-induced transcription in cancer. Semin Cancer Biol. 42:60–69. 2017. View Article : Google Scholar : PubMed/NCBI
35	Seyfried TN and Huysentruyt LC: On the origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013. View Article : Google Scholar : PubMed/NCBI
36	Lee J, Tae N, Lee JJ, Kim T and Lee JH: Eupatolide inhibits lipopolysaccharide-induced COX-2 and iNOS expression in RAW264.7 cells by inducing proteasomal degradation of TRAF6. Eur J Pharmacol. 636:173–180. 2010. View Article : Google Scholar : PubMed/NCBI
37	Schmierer B and Hill CS: TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar : PubMed/NCBI
38	Feng XH and Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 21:659–693. 2005. View Article : Google Scholar : PubMed/NCBI
39	Daly AC, Randall RA and Hill CS: Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol. 28:6889–6902. 2008. View Article : Google Scholar : PubMed/NCBI
40	Valcourt U, Kowanetz M, Niimi H, Heldin CH and Moustakas A: TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell. 16:1987–2002. 2005. View Article : Google Scholar : PubMed/NCBI
41	Connolly EC, Freimuth J and Akhurst RJ: Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 8:964–978. 2012. View Article : Google Scholar : PubMed/NCBI
42	Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B and Jachimczak P: Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17:129–139. 2006. View Article : Google Scholar : PubMed/NCBI
43	Akhurst RJ: Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs. 7:513–521. 2006.PubMed/NCBI
44	Ling LE and Lee WC: Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology. Curr Pharm Biotechnol. 12:2190–2202. 2011. View Article : Google Scholar : PubMed/NCBI
45	Smith AL, Robin TP and Ford HL: Molecular pathways: Targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 18:4514–4521. 2012. View Article : Google Scholar : PubMed/NCBI
46	Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T and Pelicci PG: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 70:93–104. 1992. View Article : Google Scholar : PubMed/NCBI
47	Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM and Derynck R: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26:3957–3967. 2007. View Article : Google Scholar : PubMed/NCBI
48	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
49	Guo X and Wang XF: Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 19:71–88. 2009. View Article : Google Scholar : PubMed/NCBI